Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Shanghai Allist Pharmaceuticals Co. Ltd. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners. Both actions are located within 1 distinct art unit, suggesting a high degree of technical similarity between the pending matters. This concentration in 1 distinct art unit for 2 pending office actions means that both cases are being reviewed within the same administrative group at the USPTO.
CHEN, PO-CHIH is the busiest examiner for the portfolio, with 1 busiest examiner pending office action. This examiner handles half of the 2 pending office actions currently active for the company. The other half is handled by the second of the 2 distinct examiners. This distribution ensures that the company's 2 pending office actions are subject to two different perspectives, even though they are within the same 1 distinct art unit.
For a patent practitioner, the fact that 2 pending office actions are in 1 distinct art unit simplifies the technical landscape, as the same departmental guidelines will likely apply to both. However, the involvement of 2 distinct examiners means that the company must still adapt to two different individual styles. Coordinating the prosecution of these 2 pending office actions is important to ensure that the 2 distinct examiners do not receive conflicting information about the company's Biotechnology & Pharmaceuticals technology.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHEN, PO-CHIH | 1 | 74.3% | +14.7% |
| MAYHEW, BRADLEY SCOTT | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18690221 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | CHEN, PO-CHIH | — |
| 18293253 | INDOLE BIPYRIMIDINE COMPOUND, AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | MAYHEW, BRADLEY SCOTT | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18690221 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | CHEN, PO-CHIH | — |
| Art Unit | Apps |
|---|---|
| 1621 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18690221 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | CHEN, PO-CHIH | 1621 | §102§112 | Non-Final OA | — | Pending | Mar 07, 2024 |
| 18293253 | INDOLE BIPYRIMIDINE COMPOUND, AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | MAYHEW, BRADLEY SCOTT | 1621 | §112 | Non-Final OA | — | Pending | Jan 29, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShanghai Allist Pharmaceuticals Co. Ltd. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Po-Chih Chen has the most, with 1 of Shanghai Allist Pharmaceuticals Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
